Boundless Bio, Inc. Common Stock
$2.81
$0.01 (+0.36%)
$2.77Day Range$2.87
Key Statistics
Market Cap
$63.69M
Shares Outstanding
22.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 28, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$2.79
Day High
$2.87
Day Low
$2.77
Volume
346.4K
VWAP
$2.80
Prev Close
$2.80
Transactions
--
Acc. Volume
--
About Boundless Bio, Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
PHARMACEUTICAL PREPARATIONSSIC 283428 employees11099 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037(858) 766-9912IPO Mar 28, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001782303
- Composite FIGI
- BBG00Q4W34T4
- Share Class FIGI
- BBG00Q4W34V1
- Ticker Root
- BOLD
- SIC Code
- 2834
About Boundless Bio, Inc. Common Stock (BOLD) Stock
Boundless Bio, Inc. Common Stock (BOLD) closed the 2026-09-18 session at $2.81, up 0.36% versus the previous close (+0.01). The stock opened at $2.79 and traded between $2.77 and $2.87 during that session. Session trading volume was 346K shares. The volume-weighted average price (VWAP) is $2.80.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Boundless Bio, Inc. Common Stock has a market capitalization of $63.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BOLD is listed on the XNAS exchange. The company employs approximately 28 people. Boundless Bio, Inc. Common Stock is headquartered in LA JOLLA, CA. The recorded listing date is 2024-03-28.
On this page you can find market BOLD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.